Barclays maintains Zimmer Biomet Holdings at Equal-Weight, raises price target to $115 from $100

Barclays kept Zimmer Biomet Holdings at Equal-Weight, raising its price target to $115 from $100, a 15% increase. This implies an 8.9% upside from the Nov 6 close of $105.59. Recent analyst targets range from $107 to $130.

Original reporting
Published Nov 9, 2026, 3:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Zimmer Biomet Holdings at Equal-Weight, raises price target to $115 from $100 — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The upward revision may attract short-term buying interest.

02

Market read

Analyst target raise could influence ZBH's near-term price action.

03

What to watch

No new operational data; price target change alone may not drive sustained move.

Relevance 6/10Novelty 6/10Timing: today

Background

Barclays' analyst note updates price target based on recent assessments.

Company-level read

Ticker impact

$ZBHBullishMedium confidence
Context

Barclays raised its price target on Zimmer Biomet Holdings to $115 from $100.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise reflects improved outlook; market may bid the stock higher.

Market effects

May lift sentiment in the medical devices sector.

Limited to US equities market.

Low global impact.

Counterpoint

Target raise could be premature if underlying earnings miss expectations.

Key entities

  • Zimmer Biomet Holdings

    Medical device manufacturer.

  • Barclays

    Investment bank providing the price target revision.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.